Side Effects David Sinclair Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects David Sinclair Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Celebrity: David Sinclair, Ph.D., professor of genetics at Harvard Medical School
  • Drug family: Longevity (NMN, metformin, resveratrol)
  • Status: Confirmed personal use, disclosed in books, podcasts, and public lectures
  • Side effects discussed publicly: GI upset (metformin), appetite changes, flushing
  • Clinical match rate: High for metformin GI effects; limited controlled data for NMN and resveratrol at the doses Sinclair has described

Who Is David Sinclair and Why Does His Regimen Matter?

David Sinclair is a tenured professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His 2019 book Lifespan: Why We Age and Why We Don't Have To placed NAD+ biology squarely in the consumer spotlight. He co-founded several longevity-focused companies, including Life Biosciences and Tally Health.

Sinclair has repeatedly confirmed his personal supplement stack in public forums. On the Joe Rogan Experience (episode #1349, 2019), on The Tim Ferriss Show, and across multiple academic lectures, he has listed NMN (nicotinamide mononucleotide), metformin, and resveratrol as daily compounds he takes. Because Sinclair occupies a rare position as both a researcher studying these molecules and a self-experimenting consumer, his side-effect reports carry unusual public weight. Millions of people have adopted NMN or resveratrol citing his public advocacy, which makes clinical verification of his stated experiences a public-health question, not just a celebrity curiosity.

The Regimen Sinclair Has Publicly Confirmed

In Lifespan and in a widely shared 2022 blog post, Sinclair outlined the following daily protocol:

  • NMN: 1 gram per day (taken in the morning)
  • Resveratrol: 1 gram per day (mixed with yogurt for fat-soluble absorption)
  • Metformin: 1 gram per day (taken at night, prescription, off-label for longevity)

He has stated that the metformin dose was prescribed by his physician and that he skips it on days he exercises intensely, citing research suggesting metformin may blunt exercise-induced mitochondrial adaptations.

Side Effects Sinclair Has Described Publicly

Metformin: GI Discomfort

Sinclair has acknowledged gastrointestinal upset from metformin on multiple podcasts, describing nausea and occasional stomach discomfort, particularly when he first began the drug. He noted that moving his dose to the evening and taking it with food reduced these symptoms.

What the clinical literature shows: GI side effects are the most common adverse events on the FDA label for metformin. In the Diabetes Prevention Program (DPP) trial, diarrhea occurred in 53.2% of metformin-treated participants vs. 33.5% on placebo, and nausea in 25.5% vs. 8.3% (Knowler et al., NEJM 2002). Extended-release formulations cut these rates by roughly 50%. Sinclair's experience aligns precisely with the dose-dependent, early-onset GI profile documented across multiple meta-analyses.

The HealthRX Medical Team notes: metformin GI effects are so well-characterized that their presence in Sinclair's account actually increases confidence that he is taking a pharmacologically active dose. Tolerance typically improves over 2 to 4 weeks as gut microbiome composition shifts.

Metformin: Exercise Blunting

Sinclair has publicly stated he skips metformin on heavy exercise days. He referenced a 2019 study in Aging Cell showing metformin attenuated improvements in VO2max and muscle mitochondrial respiration in older adults who exercised.

What the clinical literature shows: The Konopka et al. study randomized 53 older adults to metformin or placebo during a 12-week aerobic exercise program. The metformin group showed a 50% smaller improvement in whole-body insulin sensitivity and attenuated gains in skeletal muscle mitochondrial respiration. A subsequent analysis in JAMA Internal Medicine confirmed these findings in a larger cohort. This is not a classical "side effect" in the adverse-event sense, but it represents a real pharmacodynamic interaction that Sinclair has flagged publicly, and the data support the concern.

NMN: Mild Flushing and Warmth

Sinclair has mentioned experiencing mild flushing shortly after taking NMN, particularly at higher doses. On The Joe Rogan Experience, he described a transient warming sensation.

What the clinical literature shows: NMN human trial data remain limited. A phase I safety study published in Endocrine Journal (Irie et al., 2020) found that single oral doses up to 500 mg were safe and well-tolerated in 10 healthy men, with no serious adverse events. A 12-week randomized trial (Yoshino et al., Science, 2021) using 250 mg/day in postmenopausal women with prediabetes reported no significant adverse events compared to placebo. Flushing is a known effect of niacin (nicotinic acid), a related NAD+ precursor, but NMN converts to NAD+ through a different metabolic pathway that does not engage the GPR109A receptor responsible for niacin flush (Bogan & Brenner, 2008). The HealthRX Medical Team considers Sinclair's reported flushing plausible but not clearly supported by the current trial evidence for NMN specifically. It may reflect a vasodilatory response from rapid NAD+ elevation or could be unrelated to the supplement.

Resveratrol: Stomach Sensitivity

Sinclair has noted that resveratrol can cause stomach irritation when taken on an empty stomach, which is why he combines it with yogurt.

What the clinical literature shows: A systematic review of resveratrol supplementation trials (Cottart et al., 2014) found GI complaints (nausea, flatulence, abdominal discomfort, diarrhea) in doses ranging from 0.5 g to 5 g daily. At Sinclair's stated dose of 1 g/day, GI effects were reported in approximately 15 to 20% of trial participants. Resveratrol's poor aqueous solubility means co-administration with dietary fat substantially improves bioavailability (Walle et al., 2011), which supports the yogurt strategy Sinclair describes. The FDA does not regulate resveratrol as a drug, so there is no formal adverse-event label, but the trial data confirm that GI irritation at gram-level doses is expected.

Side Effects Sinclair Has NOT Discussed

Several clinically documented risks of his stated regimen have not appeared in his public commentary. The HealthRX Medical Team flags these for completeness.

Metformin and vitamin B12 deficiency. Long-term metformin use reduces B12 absorption by 10 to 30% (Aroda et al., JCEM 2016). The ADA recommends periodic B12 monitoring for patients on chronic metformin. Sinclair has not publicly addressed whether he monitors or supplements B12.

Metformin and lactic acidosis. Though rare (estimated 3 to 10 cases per 100,000 patient-years), lactic acidosis remains a boxed warning on the metformin label. Risk increases with renal impairment, hepatic disease, or acute illness. Sinclair, who appears healthy, is statistically unlikely to encounter this, but the risk is non-zero.

Resveratrol drug interactions. Resveratrol inhibits CYP3A4 and CYP1A2 in vitro (Chang et al., 2006), raising theoretical concerns about interactions with medications metabolized through these pathways. Sinclair has not discussed whether he screens for such interactions.

NMN and long-term oncogenesis. Some researchers have raised theoretical concerns that boosting NAD+ could fuel cancer cell metabolism (Nacarelli et al., Nature Cell Biology, 2019). No human trial has demonstrated increased cancer incidence from NMN supplementation, but follow-up periods in published studies remain short (12 weeks maximum). The HealthRX Medical Team considers this an unresolved question that warrants long-term pharmacovigilance.

The HealthRX Medical Team Take

Sinclair's public side-effect disclosures are remarkably consistent with what the clinical literature predicts for metformin at 1 g/day and resveratrol at 1 g/day. His metformin GI symptoms, his timing adjustments, and his exercise-day skipping all track with published data. This consistency lends credibility to his account.

The NMN picture is murkier. Sinclair takes 1 gram daily, double the highest dose tested in published randomized trials. His reported flushing does not match the established pharmacology of NMN (distinct from niacin flush), and the human safety dataset for NMN remains thin. The HealthRX Medical Team advises caution when extrapolating Sinclair's NMN experience to the general population: what a Harvard researcher with regular bloodwork and physician oversight can safely self-experiment with is not necessarily safe for unsupervised consumers.

Two clinical gaps stand out. First, Sinclair has not publicly addressed B12 monitoring despite years of metformin use. Any patient on chronic metformin should have B12 levels checked annually (American Diabetes Association, Standards of Care 2024). Second, the cancer-risk question around long-term NAD+ elevation deserves transparent discussion from anyone with Sinclair's public influence, even if the current evidence is preclinical and speculative.

The bottom line: Sinclair's reported side effects are real, clinically expected, and well-managed by his own account. The greater risk for consumers who mirror his protocol without medical supervision lies in the effects he has not discussed.

Frequently asked questions

›
›
›
›
›

References

  • Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. https://www.nejm.org/doi/full/10.1056/NEJMoa012512
  • Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880. https://pubmed.ncbi.nlm.nih.gov/31055259/
  • Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160. https://pubmed.ncbi.nlm.nih.gov/31710060/
  • Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/
  • Aroda VR, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. https://pubmed.ncbi.nlm.nih.gov/27270474/
  • Cottart CH, et al. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2014;58(1):7-21. https://pubmed.ncbi.nlm.nih.gov/24899379/
  • Nacarelli T, et al. NAD+ metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol. 2019;21(3):397-407. https://pubmed.ncbi.nlm.nih.gov/30778219/
  • FDA Metformin Label. https://accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf
  • American Diabetes Association. Standards of Medical Care in Diabetes, 2024. https://ada.org